slipped into his chair and started up his computer. After he'd typed in three different passwords and placed his index finger on the pad for identification, his computer came to life. As shortcuts to the different programs appeared on the desktop, he directed the cursor to the e-mail icon. With a double click, the program sprang to life; thirty-three messages entered the mailbox. Most of the one-line references contained various terms referring to the same topic — funding. Ignoring these, he opened the mail message from his web designers marked URGENT, and settled into his first job of the day, which was to approve the information going onto the company's web page.
The information was not really intended for non-scientific eyes, but he always tried to make the science comprehensible. He figured that the better people understood it, the less frightened of it they would be.
He adjusted the screen and began to read.
The Recombinant DNA division (RDD) focuses on transferring a fragment of DNA from one organism to a self-replicating genetic element for propagation into a foreign host cell — essentially, cloning a gene. Recombinant DNA technology is important for learning about other related technologies such as gene therapy, genetic engineering of organisms, and sequencing genomes.
Commercial benefits:
Gene therapy can be used to treat certain genetic conditions, and genetic engineering can provide disease resistance, and even improve taste or nutritional value.
The Reproductive Cloning Division (RCD) leads the way in generating an animal that has the same nuclear DNA as another or previously existing animal. It is the transfer of genetic material from the nucleus of a donor adult cell to an egg whose nucleus — and therefore its genetic material
— has been removed. Once the cloned embryo reaches a suitable stage, it is transferred to the uterus of a female host where it continues to develop until birth.
Commercial benefits:
Reproductive cloning can be used to reproduce animals with special qualities, or in the cloning of endangered species.
The Therapeutic Cloning Division (TCD) specializes in the production of human embryos for use in research.
Commercial benefits:
Harvesting of stem cells that can be used to study human development, and therefore treat disease.
Klaus added a few notes to the TCD heading and sent the e-mail off to the web designers. As he looked through his messages again, one stood out.
At first he didn't believe it, and it almost went the way of all spam
— to the trash. 'US$25 Million R&D Grant' read the subject line.
Maybe he was bored, or maybe it was the fact that, in the past week, funding had become the focus of the company's discussion topics at board meetings; whatever the reason, he opened the e-mail.
My client is looking to put up US$25 million as a grant to the company that shows exemplary work in science — in particular, the area of cloning. Your company has been selected as one of the very few facilities able to fulfil our challenge. To find out more, and to register your interest, click on the direct link below.
The message was simple, to the point, and it had all the hallmarks of a scam, but before he could think about it, his cursor was already over the link. He clicked and the full web page came to life. Music started and flashes of information began to appear on the screen.
Once the song and dance had finished, it settled to a static home page.
It read:
US$25 Million Dollar Challenge
Clone the King of Kings
Klaus was astonished, but he read on.
Never before has the cloning industry been presented with such a challenge. Cloning was revolutionized in 1997, when
Ian Wilmut and his colleagues cloned Dolly the sheep; since then the ethics of human cloning have been debated among us all, as well as in the international courts. Now, our historic challenge to you is to clone Jesus.
The terms and conditions of the challenge do not stop at the embryo or infant stage. We want